日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

自体多抗原靶向T细胞疗法治疗胰腺癌:一项1/2期试验

Musher, Benjamin L; Vasileiou, Spyridoula; Smaglo, Brandon G; Robertson, Catherine S; Wu, Mengfen; Wang, Tao; Watanabe, Ayumi; Kuvalekar, Manik; Velazquez, Yovana; Ketkar, Shamika; Doheyan, Tamadar Al; Papayanni, Penelope G; Shah, Aakash; Lapteva, Natalia; Grilley, Bambi J; Van Buren, George; Lulla, Premal D; Heslop, Helen E; Rooney, Cliona M; Brenner, Malcolm K; Leen, Ann M

Macrophages as gatekeepers of glioma progression

巨噬细胞作为胶质瘤进展的守门人

Rooney, Cliona M; Mahdi, Jasia

Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control

组成型IL-7信号传导促进CAR-NK细胞在实体瘤微环境中的存活,但会削弱肿瘤控制。

Dysthe, Matthew; Navin, Ishwar; van Leeuwen, Dayenne; Pineda, Josue; Baumgartner, Corrine; Rooney, Cliona M; Parihar, Robin

Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas

EBV相关淋巴瘤患者接受EBVST免疫治疗后,针对EBV蛋白质组的差异性抗体反应

Sarathkumara, Yomani D; Van Bibber, Nathan W; Liu, Zhiwei; Heslop, Helen E; Rouce, Rayne H; Coghill, Anna E; Rooney, Cliona M; Proietti, Carla; Doolan, Denise L

Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.

外源肽加载后 T 细胞受体对乳腺癌热点突变 ESR1 Y537S 和 D538G 的识别与内源抗原加工后的识别不一致

Shafer Paul, Leung Wingchi K, Woods Mae, Choi Jong Min, Rodriguez-Plata Carlos M, Maknojia Arushana, Mosquera Andres, Somes Lauren K, Joubert Jarrett, Manliguez Anthony, Ranjan Rashi, Burt Bryan, Lee Hyun-Sung, Zhang Bing, Fuqua Suzanne, Rooney Cliona, Leen Ann M, Hoyos Valentina

Differential EBV protein-specific antibody response between responders and non-responders to EBVSTs immunotherapy

EBVSTs免疫疗法应答者和非应答者之间EBV蛋白特异性抗体反应的差异

Sarathkumara, Yomani D; Van Bibber, Nathan W; Liu, Zhiwei; Heslop, Helen E; Rouce, Rayne H; Coghill, Anna E; Rooney, Cliona M; Proietti, Carla; Doolan, Denise L

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma

接受 GD2 靶向嵌合抗原受体修饰的免疫效应细胞治疗神经母细胞瘤后,患者生存期达 18 年。

Che-Hsing, Li; Sharma, Sandhya; Heczey, Andras A; Steffin, David H M; Louis, Chrystal U; Grilley, Bambi J; Thakkar, Sachin G; Wu, Mengfen; Wang, Tao; Rooney, Cliona M; Brenner, Malcolm K; Heslop, Helen E

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

寄希望于病毒特异性T细胞来满足现成细胞疗法的需求

Quach, David H; Lulla, Premal; Rooney, Cliona M

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients

用于治疗高危患者 COVID-19 的同种异体、现成的 SARS-CoV-2 特异性 T 细胞 (ALVR109)

Vasileiou, Spyridoula; Hill, LaQuisa; Kuvalekar, Manik; Workineh, Aster G; Watanabe, Ayumi; Velazquez, Yovana; Lulla, Suhasini; Mooney, Kimberly; Lapteva, Natalia; Grilley, Bambi J; Heslop, Helen E; Rooney, Cliona M; Brenner, Malcolm K; Eagar, Todd N; Carrum, George; Grimes, Kevin A; Leen, Ann M; Lulla, Premal

Longitudinal analysis of the evolution of cellular immunity to SARS-CoV-2 induced by infection and vaccination

对感染和疫苗接种诱导的针对 SARS-CoV-2 的细胞免疫演变进行纵向分析

Vasileiou, Spyridoula; Kuvalekar, Manik; Velazquez, Yovana; Watanabe, Ayumi; Narula, Mansi; Workineh, Aster G; French-Kim, Matthew; Chavez, Alejandro Torres; Gilmore, Sarah; Rooney, Cliona M; Leen, Ann M